2025. Therapeutic Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Dyslipidemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Althea Medical Journal. 12, 3 (Sep. 2025), 161–171. DOI:https://doi.org/10.15850/amj.v12n3.4209.